Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
267 articles with Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc. Presents Data Associated With Its Novel Anticoagulation Assay At American Heart Association Scientific Sessions
Portola Pharmaceuticals, Inc. Advances ADP Program: Initiates Phase I Trial With IV Formulation, Trials With Oral Formulation Ongoing
Portola Pharmaceuticals, Inc. Announces The Appointment Of Peggy V. Phillips To Its Board Of Directors
Portola Pharmaceuticals, Inc. Announces Initiation Of Phase II Clinical Trial With Factor Xa Inhibitor
Portola Pharmaceuticals, Inc. Raises $46 Million Series B Financing To Advance Cardiovascular Portfolio